Sarepta Therapeutics (SRPT) PT Lowered to $16 at BofA Securities, 'Debt refinancing mitigates liquidity risk but Elevidys launch remains overhang'
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $16.00 (from $17.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
